Blood pressure control in type 2 diabetic patients.

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
Liraglutide 1 endocrinologydiseasesdrugs
amiloride 1 endocrinologydiseasesdrugs
dapagliflozin 5 endocrinologydiseasesdrugs
diabetes mellitus 5 endocrinologydiseases
hypoglycemia 1 endocrinologydiseases
obesity 1 endocrinologydiseases
spironolactone 4 endocrinologydiseasesdrugs

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
Liraglutide 36797 sympathetic nervous system activation [[98]] and this may result in BP elevation. In the recently published Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial [[99]], patients
amiloride 35073 as well. In a large group of patients with stage I hypertension a combination of chlorthalidone and amiloride yielded a greater reduction in BP than the ARB losartan [[94]]. In patients requiring triple therapy,
dapagliflozin 38301 inhibitorsThree representatives of this new class of anti-diabetics are currently in the market-canagliflozin, dapagliflozin and empagliflozin. Some others are under development. Although agents differ in their affinity for the
dapagliflozin 38920 by 4 and 1.6 mmHg compared with placebo [[108]]. A pooled analysis of studies of canagliflozin and dapagliflozin concluded that orthostatic hypotension was not increased during treatment with these SGLT2 inhibitors
dapagliflozin 39209 meta-analysis specifically evaluated the effect of SGLT2 inhibitors on BP in diabetic individuals. The dapagliflozin BP study [[109]] reported a 4.28 mmHg statistically significant decrease in seated systolic BP during
dapagliflozin 39735 systolic BP recorded by 24H ambulatory blood pressure monitoring after 12 weeks of treatment with dapagliflozin [[110]]. The Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG)
dapagliflozin 42041 results of the Canagliflozin Cardiovascular Assessment Study (CANVAS) [[116]] and DECLARE-TIMI 55 (for dapagliflozin ) [[117]] studies which are expected to be complete on 2017 and 2019 respectively will clarify whether
spironolactone 31960 hypertension and prostate hyperplasia or as third or fourth-line agents.Aldosterone antagonistsLow dose spironolactone was found to be effective in controlling BP in patients with hypertension and diabetes [[82]]. The addition
spironolactone 32086 to be effective in controlling BP in patients with hypertension and diabetes [[82]]. The addition of spironolactone is particularly effective in those with serum potassium of <4.5 mmol/L [[83]]. To prevent hyperkalemia
spironolactone 32325 thiazide like diuretics should be continued when aldosterone antagonists are added [[84]]. The addition of spironolactone to conventional antihypertensive treatment in diabetic patients was shown to reduce albuminuria [[85]]
spironolactone 32779 [[86]]. Finerenone is a new non-steroidal anti mineralocorticoid which has less relative affinity than spironolactone and eplerenone to other steroid hormone receptors, and therefore has less adverse effects like gynaecomastia,
Select Disease Character Offset Disease Term Instance
diabetes mellitus 1536 discuss the new diabetic drug classes and their influence on BP.BackgroundEssential hypertension and diabetes mellitus (DM) are both extremely common conditions and therefore it is not surprising that their co-existence
diabetes mellitus 4761 [[28], [29]], however how low should BP be is controversial.What should be the blood pressure target in diabetes mellitus ?The BP targets in diabetic hypertensive individuals are controversial. For many years it was common
diabetes mellitus 15799 (years)Main conclusionsEffect of antihypertensive treatment at different BP levels in patients with diabetes mellitus [[47]]2016British Medical Journal4973,738Only diabetic, most type 23.7If BP was greater than 150 mmHg,
diabetes mellitus 17021 which smaller, but significant, risk reductions were detectedBP targets for hypertension in people with diabetes mellitus [[48]]2013Cochrane Database systematic reviews5731471344.5Reduction in incidence of stroke in intensive
diabetes mellitus 30565 hypertension.DiureticsAlthough there has been concern that diuretics might increase the risk for the development of diabetes mellitus [[75]] due to their potential to negatively influence insulin resistance [[76]], diuretics are important
hypoglycemia 28047 including an increase in triglyceride levels, a decrease in HDL cholesterol levels, weight gain, masking hypoglycemia and impairing insulin sensitivity [[67]]. In addition, it has been suggested that use of beta blockers
obesity 3328 treatment is persistent BP values ≥140/90 mmHg. As both hypertension and DM are highly associated with obesity , it is not surprising that their co-existence is particularly common in obese individuals [[9]]. Both

You must be authorized to submit a review.